GLEEVEC (IMATINIB): A BREAKTHROUGH IN CANCER TREATMENT

Journal Title: Journal of Biomedical and Pharmaceutical Research - Year 2016, Vol 5, Issue 6

Abstract

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of various cancers and represents a therapeutic breakthrough. Imatinib was one of the first cancer therapies to show the potential for such targeted action. Imatinib, an oral targeted therapy, inhibits tyrosine kinases specifically BCR-ABL, c-KIT, and PDGFRA. Apart from its remarkable success in CML and GIST, Imatinib benefits various other tumors caused by Imatinib-specific abnormalities of PDGFR and c-KIT. Imatinib has also been proven to be effective in steroid-refractory chronic graft-versus-host disease because of its anti-PDGFR action. Gleevec has been approved for the treatment of patients with positive inoperable and/or metastatic malignant gastrointestinal stromal tumors (GISTs). Gleevec is a signal transduction inhibitor that works by targeting the activity of enzymes called tyrosine kinases. The activity of one of these tyrosine kinases, known as c-kit, is thought to drive the growth and division of most GISTs. Key words: CML, GIST, PDGFRA

Authors and Affiliations

Sakshi Minocha

Keywords

Related Articles

PREVALENCE OF MYCOBACTERIUM TUBERCULOSIS AMONG SMOKERS

The convergence of these two important health hazards is likely severely affecting India’s TB control programs. This study was carried out to determine the prevalence of smoking in newly diagnosed pulmonary TB patients a...

GLEEVEC (IMATINIB): A BREAKTHROUGH IN CANCER TREATMENT

Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers. Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed the approach to management of vari...

Pulmonary hypertension; aetio-pathogenesis, current treatment and future prospects

Pulmonary hypertension (PH) is a vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the ri...

Self-medication and role of pharmacist in patient education

Introduction: Pharmacy is the art, science and practice of preparing, preserving, compounding and dispensing of drugs and it also includes modern services related to health care including clinical services, reviewing med...

A correlation study to establish a correlation between kinesiophobia with disability and mechanical factors in subjects with chronic non – specific low back pain

Back problem has become the most expensive musculoskeletal malady in the industrialized nation of the world. It is the common affliction whose specific cause and precise treatment are still baffling to the medical profes...

Download PDF file
  • EP ID EP418080
  • DOI -
  • Views 128
  • Downloads 0

How To Cite

Sakshi Minocha (2016). GLEEVEC (IMATINIB): A BREAKTHROUGH IN CANCER TREATMENT. Journal of Biomedical and Pharmaceutical Research, 5(6), 137-152. https://europub.co.uk/articles/-A-418080